Apheris

Apheris, founded in 2019, is at the forefront of integrating AI solutions into the life sciences sector. With a focus on drug discovery, the company offers enterprise-grade applications designed to be securely run and customized within the pharmaceutical companies' own IT environments. This approach ensures that organizations maintain full control over their IP-sensitive assets, essential in the highly competitive pharmaceutical industry.

The unique proposition of Apheris lies in its federated data networks, facilitating collaborations where companies can train and benchmark models on proprietary datasets. This collaboration enhances the discovery process and generates more robust models, ultimately leading to more effective drug development.

Recently, Apheris secured a significant $20.80M Series A investment on 01 January 2025 from leading investors including LocalGlobe & Latitude, Octopus Ventures, and Heal Capital, validating the company's innovative approach and potential in the industry. Headquartered in Germany, Apheris operates at the intersection of AI, Analytics, Cyber Security, and Machine Learning, making it a compelling prospect in the evolving landscape of pharmaceutical research and development.